NR4A1 and breast cancer: Furthermore, unlike hormone therapy and HER2-guided therapy, which produce considerable positive results in hormone receptor (HR)-positive and HER2-positive BC, readily targeted drugs are absent to treat TNBCs compared to other molecular subtypes of BC.